MD | Tehran University of Medical Sciences | Iran
Dr. Shayan Zamani is a dedicated Clinical Research Fellow at the Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, where he has established a strong foundation in dermatology, oncology, and hematopoietic stem cell transplantation. He earned his Doctor of Medicine (MD) with a focus on dermatologic research and clinical therapeutics, combining his medical expertise with evidence-based research in complex dermatological and oncologic disorders. Throughout his career, Dr. Zamani has contributed to multidisciplinary research collaborations exploring topics such as graft-versus-host disease (GVHD), drug-resistant fungal infections, cutaneous complications in oncology patients, and innovative nanoliposomal treatments for fungal and inflammatory skin diseases. His professional experience spans both clinical and laboratory environments, where he integrates translational methodologies to improve diagnostic precision and patient outcomes. His research interests center on dermatologic oncology, infectious skin diseases, immunodermatology, and regenerative therapies, supported by his skills in clinical trial design, biomarker analysis, molecular diagnostics, and data-driven evaluation of treatment efficacy. Dr. Zamani has authored several peer-reviewed publications in reputable journals such as JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Frontiers in Oncology, and Dermatologic Therapy, contributing valuable insights into skin disease pathophysiology and treatment optimization. His work has earned him recognition for academic excellence and commitment to advancing medical science. Dr. Zamani has actively participated in research collaborations and conferences, reflecting strong leadership and dedication to clinical innovation. With a growing publication record and a clear focus on improving therapeutic outcomes, he continues to strengthen his role in advancing dermatologic and oncologic research globally. His academic impact is demonstrated by 19 citations , 11 publications, and an h-index of 3.
Profiles : Google Scholar | Scopus | ORCID
Featured Publications
1. Tamimi, P., Fattahi, M., Ghaderi, A., Firooz, A., Shirvani, F., Alkhen, A., & Zamani, S. (2024). Terbinafin‐resistente Trichophyton indotineae mit F397L/L393S‐ oder F397L/L393F‐Mutation bei Patienten mit Tinea incognita unter Glukokortikosteroiden. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 22(7), 922–935.
2. Samadi, A., Ayatollahi, A., Kashani, M. N., Zamani, S., & Firooz, A. (2023). Efficacy and tolerability assessment of a polynucleotide‐based gel for improvement of pattern hair loss: A polynucleotide‐based gel for improvement of pattern hair loss. [Journal name not specified].
3. Mehdizadeh, M., Tehrani, H. A., Rezvani, H., Zamani, S., Salari, S., & Hajifathali, A. (2023). Maintenance therapy with Everolimus in patients with refractory or relapsing Hodgkin lymphoma after autologous stem cell transplantation. Blood Cell Therapy, 6(3), 87–93.
4. Zamani, S., Azhdari, H., & Mehdizadeh, M. (2023). Efficacy and safety profile of Everolimus as a maintenance therapy for primary refractory/relapsing Hodgkin lymphoma following autologous hematopoietic stem cell transplantation. HemaSphere, 7(S3), e9236902.
5. Zamani, S., Mehdizadeh, M., & Salem, A. (2023). Allogeneic stem cell transplantation outcomes in Hodgkin lymphoma: A prognostic study of 30 patients with relapsed and refractory Hodgkin lymphoma. HemaSphere, 7(S3), e621289b.